SpineGuard Expands Its Intellectual Property

  • Original utilization of ultrasounds to complement the DSG guidance technology
  • X-Ray free determination of entry point and trajectory in bone
  • Grant of two new patents in Japan and China

PARIS & BOULDER, Colo.–(BUSINESS WIRE)–Regulatory News:

SpineGuard (Paris:ALSGD) (FR0011464452 – ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, announces today the grant of two new patents in Japan and China.

The invention presented in the patents consists of implementing ultrasound technology in an original manner in order to determine without X-Rays and from the surface of the bone, the position of the entry point and the optimal trajectory for a bone drilling instrument.

Stéphane Bette, Deputy CEO and co-founder of SpineGuard, said: For several years SpineGuard has been inventing and assembling complementary technical solutions for positioning instruments and implants precisely and safely in bone, while alleviating the systematic dangerous recourse to X-Ray imaging. The invention that is validated here has the potential to complement our DSG sensing technology. Indeed, it may allow the surgeon, or the surgical robot, to find from the surface of the bone the position of the entry point as well as the optimal trajectory. Once the instrument has penetrated the entry point, our DSG sensor in the bone will optimize the prevention of breaches. China and Japan are the second and third largest markets for medical devices today, they are therefore a significant stake in terms of intellectual property. Our IP portfolio continues to strengthen and feeds our discussions toward structuring strategic alliances.

About SpineGuard®

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 75,000 surgical procedures worldwide. Fifteen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these solid fundamentals and several strategic partnerships, SpineGuard has expanded its technology platform in a disruptive innovation: the « smart » pedicle screw launched late 2017 and is broadening the scope of applications in dental implantology and surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer.

For further information, visit www.spineguard.com


The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.


Pierre Jérôme
CEO & Chairman
Tel.: +33 1 45 18 45 19

Manuel Lanfossi
Tél.: +33 1 45 18 45 19

Investor Relations & Financial Communication
Mathilde Bohin / Pierre Laurent
Tel.: +33 1 44 71 94 94

SOURCE: Business Wire, 10th July 2020